These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 28273791)
21. DICER/AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD. Lim JW; Snider L; Yao Z; Tawil R; Van Der Maarel SM; Rigo F; Bennett CF; Filippova GN; Tapscott SJ Hum Mol Genet; 2015 Sep; 24(17):4817-28. PubMed ID: 26041815 [TBL] [Abstract][Full Text] [Related]
22. DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis. Knopp P; Krom YD; Banerji CR; Panamarova M; Moyle LA; den Hamer B; van der Maarel SM; Zammit PS J Cell Sci; 2016 Oct; 129(20):3816-3831. PubMed ID: 27744317 [TBL] [Abstract][Full Text] [Related]
24. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy. Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777 [TBL] [Abstract][Full Text] [Related]
25. FSHD myotubes with different phenotypes exhibit distinct proteomes. Tassin A; Leroy B; Laoudj-Chenivesse D; Wauters A; Vanderplanck C; Le Bihan MC; Coppée F; Wattiez R; Belayew A PLoS One; 2012; 7(12):e51865. PubMed ID: 23272181 [TBL] [Abstract][Full Text] [Related]
26. Adenine base editing of the Šikrová D; Cadar VA; Ariyurek Y; Laros JFJ; Balog J; van der Maarel SM Mol Ther Nucleic Acids; 2021 Sep; 25():342-354. PubMed ID: 34484861 [TBL] [Abstract][Full Text] [Related]
27. Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing. Jones TI; Yan C; Sapp PC; McKenna-Yasek D; Kang PB; Quinn C; Salameh JS; King OD; Jones PL Clin Epigenetics; 2014; 6(1):23. PubMed ID: 25400706 [TBL] [Abstract][Full Text] [Related]
28. Facioscapulohumeral muscular dystrophy: Are telomeres the end of the story? Stadler G; King OD; Robin JD; Shay JW; Wright WE Rare Dis; 2013; 1():e26142. PubMed ID: 25003004 [TBL] [Abstract][Full Text] [Related]
29. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level. Banerji CRS; Zammit PS Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic Strategies Targeting DUX4 in FSHD. Le Gall L; Sidlauskaite E; Mariot V; Dumonceaux J J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32906621 [TBL] [Abstract][Full Text] [Related]
31. Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy. Bao B; Maruyama R; Yokota T Intractable Rare Dis Res; 2016 Aug; 5(3):168-76. PubMed ID: 27672539 [TBL] [Abstract][Full Text] [Related]
32. Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells. Lim KRQ; Yokota T Methods Mol Biol; 2023; 2587():197-208. PubMed ID: 36401032 [TBL] [Abstract][Full Text] [Related]
33. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy. Feng Q; Snider L; Jagannathan S; Tawil R; van der Maarel SM; Tapscott SJ; Bradley RK Elife; 2015 Jan; 4():. PubMed ID: 25564732 [TBL] [Abstract][Full Text] [Related]
34. WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy. Mocciaro E; Giambruno R; Micheloni S; Cernilogar FM; Andolfo A; Consonni C; Pannese M; Ferri G; Runfola V; Schotta G; Gabellini D Nucleic Acids Res; 2023 Jun; 51(10):5144-5161. PubMed ID: 37021550 [TBL] [Abstract][Full Text] [Related]
35. Antisense targeting of 3' end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach. Marsollier AC; Ciszewski L; Mariot V; Popplewell L; Voit T; Dickson G; Dumonceaux J Hum Mol Genet; 2016 Apr; 25(8):1468-78. PubMed ID: 26787513 [TBL] [Abstract][Full Text] [Related]
36. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Wallace LM; Garwick SE; Mei W; Belayew A; Coppee F; Ladner KJ; Guttridge D; Yang J; Harper SQ Ann Neurol; 2011 Mar; 69(3):540-52. PubMed ID: 21446026 [TBL] [Abstract][Full Text] [Related]
37. A unifying genetic model for facioscapulohumeral muscular dystrophy. Lemmers RJ; van der Vliet PJ; Klooster R; Sacconi S; Camaño P; Dauwerse JG; Snider L; Straasheijm KR; van Ommen GJ; Padberg GW; Miller DG; Tapscott SJ; Tawil R; Frants RR; van der Maarel SM Science; 2010 Sep; 329(5999):1650-3. PubMed ID: 20724583 [TBL] [Abstract][Full Text] [Related]
38. Aberrant splicing in transgenes containing introns, exons, and V5 epitopes: lessons from developing an FSHD mouse model expressing a D4Z4 repeat with flanking genomic sequences. Ansseau E; Domire JS; Wallace LM; Eidahl JO; Guckes SM; Giesige CR; Pyne NK; Belayew A; Harper SQ PLoS One; 2015; 10(3):e0118813. PubMed ID: 25742305 [TBL] [Abstract][Full Text] [Related]